Dr Reddys launches generic version of AndroGel in US market

The company's testosterone gel 1.62 per cent, which is a therapeutic equivalent generic version of AndroGel 1.62 per cent of AbbVie Inc, was approved by the US Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing.

New Delhi: Drug maker Dr Reddy's Laboratories Monday said it has launched in the US market its generic version of AndroGel testosterone gel which is used in treating adult males with low or no testosterone due to certain medical conditions.

Also Read: Dr Reddys, Cipla arm recall drugs in US; includes 7.8 lakh vials of Testosterone Cypionate injection

The company's testosterone gel 1.62 per cent, which is a therapeutic equivalent generic version of AndroGel 1.62 per cent of AbbVie Inc, was approved by the US Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing.

Also Read: After 11 years, Dr Reddys Lab gets Chinese regulator nod for generic Clopidogrel

Citing IQVIA Health data for the 12 months ended February 2019, the company said AndroGel brand and generic versions had US sales of around USD 815.6 million.

Dr Reddy’s Lab was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad.

Dr Reddy’s manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.